[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fcVziC7jOjN9s9pK_3aH9jg50cRFmTabrLHHDhZAfSXY":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":7,"truncated":8,"activeTrials":9,"phase3Count":10,"totalEnrollment":11,"activePrograms":12,"nonDrugCount":13,"topConditions":14,"upcomingReadouts":33,"phaseBuckets":54,"rows":61},"University of Hawaii",[4,6],"University of Hawaii Cancer Research Center",96,false,20,6,33741,4,68,[15,18,20,22,24,26,28,31],{"name":16,"count":17},"Type 2 Diabetes",7,{"name":19,"count":10},"Obesity",{"name":21,"count":10},"Hypertension",{"name":23,"count":12},"Physical Activity",{"name":25,"count":12},"Breast Cancer",{"name":27,"count":12},"Overweight and Obesity",{"name":29,"count":30},"HIV Infections",3,{"name":32,"count":30},"HIV",[34,39,44,49],{"nctId":35,"briefTitle":36,"date":37,"intervention":38},"NCT03680508","TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer","2026-03-06","TSR-022 and TSR-042",{"nctId":40,"briefTitle":41,"date":42,"intervention":43},"NCT06935838","Effects of Tirzepatide on Weight Loss and Chronic Inflammation in People With HIV","2026-07-31","Tirzepatide",{"nctId":45,"briefTitle":46,"date":47,"intervention":48},"NCT07075120","Ipilimumab and Nivolumab With SBRT in Locally Advanced Hepatocellular Cancer","2027-08-01","Ipilimumab and Nivolumab",{"nctId":50,"briefTitle":51,"date":52,"intervention":53},"NCT07075575","Quit-Smoking Study for Native Hawaiians","2027-11-01","Nicotine Polacrilex Gum",[55,56,57,58,59,60],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[62,89,112,134,157,186,204,230,256,274,301,319,354,380,405,429,453,478,504,522,540,558,585,610,633,660,684,710,728,751,775,793,817,842,867,885],{"intervention":38,"totalTrials":63,"cells":64},1,{"EARLY_PHASE1":65,"PHASE1":68,"PHASE2":70,"PHASE3":83,"PHASE4":85,"NA":87},{"trials":66,"activeCount":67},[],0,{"trials":69,"activeCount":67},[],{"trials":71,"activeCount":63,"soonestReadout":37},[72],{"nctId":35,"briefTitle":36,"status":73,"phases":74,"primaryCompletion":37,"completion":75,"start":76,"enrollment":77,"conditions":78,"interventions":82},"ACTIVE_NOT_RECRUITING",[57],"2027-10","2019-12-19",42,[79,80,81],"Adult Primary Liver Cancer","Advanced Adult Primary Liver Cancer","Localized Unresectable Adult Primary Liver Cancer",[38],{"trials":84,"activeCount":67},[],{"trials":86,"activeCount":67},[],{"trials":88,"activeCount":67},[],{"intervention":43,"totalTrials":63,"cells":90},{"EARLY_PHASE1":91,"PHASE1":93,"PHASE2":95,"PHASE3":106,"PHASE4":108,"NA":110},{"trials":92,"activeCount":67},[],{"trials":94,"activeCount":67},[],{"trials":96,"activeCount":63,"soonestReadout":42},[97],{"nctId":40,"briefTitle":41,"status":98,"phases":99,"primaryCompletion":42,"completion":42,"start":100,"enrollment":101,"conditions":102,"interventions":105},"RECRUITING",[57],"2025-11-12",12,[103,32,104],"Obesity and Overweight","Chronic Inflammation",[43],{"trials":107,"activeCount":67},[],{"trials":109,"activeCount":67},[],{"trials":111,"activeCount":67},[],{"intervention":48,"totalTrials":63,"cells":113},{"EARLY_PHASE1":114,"PHASE1":116,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":132},{"trials":115,"activeCount":67},[],{"trials":117,"activeCount":63,"soonestReadout":47},[118],{"nctId":45,"briefTitle":46,"status":98,"phases":119,"primaryCompletion":47,"completion":120,"start":121,"enrollment":122,"conditions":123,"interventions":125},[56],"2027-12-31","2026-04-01",15,[124],"Hepatocellular Carcinoma (HCC)",[48],{"trials":127,"activeCount":67},[],{"trials":129,"activeCount":67},[],{"trials":131,"activeCount":67},[],{"trials":133,"activeCount":67},[],{"intervention":53,"totalTrials":63,"cells":135},{"EARLY_PHASE1":136,"PHASE1":138,"PHASE2":140,"PHASE3":142,"PHASE4":144,"NA":146},{"trials":137,"activeCount":67},[],{"trials":139,"activeCount":67},[],{"trials":141,"activeCount":67},[],{"trials":143,"activeCount":67},[],{"trials":145,"activeCount":67},[],{"trials":147,"activeCount":63,"soonestReadout":52},[148],{"nctId":50,"briefTitle":51,"status":149,"phases":150,"primaryCompletion":52,"completion":151,"start":121,"enrollment":152,"conditions":153,"interventions":156},"NOT_YET_RECRUITING",[60],"2028-04-01",75,[154,155],"Tobacco Use Disorder","Smoking Cessation",[53],{"intervention":158,"totalTrials":63,"cells":159},"Raltegravir",{"EARLY_PHASE1":160,"PHASE1":162,"PHASE2":164,"PHASE3":166,"PHASE4":168,"NA":184},{"trials":161,"activeCount":67},[],{"trials":163,"activeCount":67},[],{"trials":165,"activeCount":67},[],{"trials":167,"activeCount":67},[],{"trials":169,"activeCount":67},[170],{"nctId":171,"briefTitle":172,"status":173,"phases":174,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":179,"interventions":182},"NCT01147107","Hepatic Safety of Raltegravir Versus Efavirenz as HIV Therapy for Patients With HIV and HCV Coinfection","COMPLETED",[59],"2016-06-01","2021-06-01","2014-02",80,[180,181],"Hepatitis C, Chronic","HIV Infection",[158,183],"Efavirenz",{"trials":185,"activeCount":67},[],{"intervention":183,"totalTrials":63,"cells":187},{"EARLY_PHASE1":188,"PHASE1":190,"PHASE2":192,"PHASE3":194,"PHASE4":196,"NA":202},{"trials":189,"activeCount":67},[],{"trials":191,"activeCount":67},[],{"trials":193,"activeCount":67},[],{"trials":195,"activeCount":67},[],{"trials":197,"activeCount":67},[198],{"nctId":171,"briefTitle":172,"status":173,"phases":199,"primaryCompletion":175,"completion":176,"start":177,"enrollment":178,"conditions":200,"interventions":201},[59],[180,181],[158,183],{"trials":203,"activeCount":67},[],{"intervention":205,"totalTrials":63,"cells":206},"Pregabalin",{"EARLY_PHASE1":207,"PHASE1":209,"PHASE2":211,"PHASE3":213,"PHASE4":215,"NA":228},{"trials":208,"activeCount":67},[],{"trials":210,"activeCount":67},[],{"trials":212,"activeCount":67},[],{"trials":214,"activeCount":67},[],{"trials":216,"activeCount":67},[217],{"nctId":218,"briefTitle":219,"status":173,"phases":220,"primaryCompletion":221,"completion":222,"start":223,"enrollment":224,"conditions":225,"interventions":227},"NCT02782169","Prophylactic Pregabalin to Decrease Pain During Medical Abortion",[59],"2016-10","2016-12","2015-06",110,[226],"Acute Pain",[205],{"trials":229,"activeCount":67},[],{"intervention":231,"totalTrials":63,"cells":232},"Lidocaine",{"EARLY_PHASE1":233,"PHASE1":235,"PHASE2":237,"PHASE3":239,"PHASE4":241,"NA":254},{"trials":234,"activeCount":67},[],{"trials":236,"activeCount":67},[],{"trials":238,"activeCount":67},[],{"trials":240,"activeCount":67},[],{"trials":242,"activeCount":67},[243],{"nctId":244,"briefTitle":245,"status":173,"phases":246,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":250,"interventions":252},"NCT03107754","Buffered Lidocaine in Paracervical Blocks",[59],"2018-10-25","2017-05-15",98,[251],"Pain",[231,253],"Lidocaine-Sodium Bicarbonate",{"trials":255,"activeCount":67},[],{"intervention":253,"totalTrials":63,"cells":257},{"EARLY_PHASE1":258,"PHASE1":260,"PHASE2":262,"PHASE3":264,"PHASE4":266,"NA":272},{"trials":259,"activeCount":67},[],{"trials":261,"activeCount":67},[],{"trials":263,"activeCount":67},[],{"trials":265,"activeCount":67},[],{"trials":267,"activeCount":67},[268],{"nctId":244,"briefTitle":245,"status":173,"phases":269,"primaryCompletion":247,"completion":247,"start":248,"enrollment":249,"conditions":270,"interventions":271},[59],[251],[231,253],{"trials":273,"activeCount":67},[],{"intervention":275,"totalTrials":63,"cells":276},"Stribild",{"EARLY_PHASE1":277,"PHASE1":279,"PHASE2":281,"PHASE3":283,"PHASE4":285,"NA":299},{"trials":278,"activeCount":67},[],{"trials":280,"activeCount":67},[],{"trials":282,"activeCount":67},[],{"trials":284,"activeCount":67},[],{"trials":286,"activeCount":67},[287],{"nctId":288,"briefTitle":289,"status":290,"phases":291,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":296,"interventions":297},"NCT02283060","Sleep and Cognition After Atripla to Stribild Switch","UNKNOWN",[59],"2016-07","2016-08","2014-09",30,[32],[275,298],"Atripla",{"trials":300,"activeCount":67},[],{"intervention":298,"totalTrials":63,"cells":302},{"EARLY_PHASE1":303,"PHASE1":305,"PHASE2":307,"PHASE3":309,"PHASE4":311,"NA":317},{"trials":304,"activeCount":67},[],{"trials":306,"activeCount":67},[],{"trials":308,"activeCount":67},[],{"trials":310,"activeCount":67},[],{"trials":312,"activeCount":67},[313],{"nctId":288,"briefTitle":289,"status":290,"phases":314,"primaryCompletion":292,"completion":293,"start":294,"enrollment":295,"conditions":315,"interventions":316},[59],[32],[275,298],{"trials":318,"activeCount":67},[],{"intervention":320,"totalTrials":321,"cells":322},"maraviroc",2,{"EARLY_PHASE1":323,"PHASE1":325,"PHASE2":327,"PHASE3":338,"PHASE4":350,"NA":352},{"trials":324,"activeCount":67},[],{"trials":326,"activeCount":67},[],{"trials":328,"activeCount":67},[329],{"nctId":330,"briefTitle":331,"status":173,"phases":332,"primaryCompletion":333,"completion":334,"start":335,"enrollment":122,"conditions":336,"interventions":337},"NCT00987948","Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels",[57],"2012-11","2013-08","2010-01",[29],[320],{"trials":339,"activeCount":67},[340],{"nctId":341,"briefTitle":342,"status":173,"phases":343,"primaryCompletion":344,"completion":344,"start":223,"enrollment":345,"conditions":346,"interventions":348},"NCT02159027","Maraviroc and NeuroAIDS Pathogenesis",[57,58],"2019-02",48,[347],"AIDS Dementia Complex",[349],"Maraviroc",{"trials":351,"activeCount":67},[],{"trials":353,"activeCount":67},[],{"intervention":355,"totalTrials":63,"cells":356},"Metformin",{"EARLY_PHASE1":357,"PHASE1":359,"PHASE2":361,"PHASE3":363,"PHASE4":376,"NA":378},{"trials":358,"activeCount":67},[],{"trials":360,"activeCount":67},[],{"trials":362,"activeCount":67},[],{"trials":364,"activeCount":67},[365],{"nctId":366,"briefTitle":367,"status":290,"phases":368,"primaryCompletion":369,"completion":370,"start":371,"enrollment":372,"conditions":373,"interventions":375},"NCT04500678","Impact of Metformin on Immuno-virologic Parameters in HIV",[57,58],"2022-02-01","2022-12-31","2019-02-01",38,[374],"HIV\u002FAIDS",[355],{"trials":377,"activeCount":67},[],{"trials":379,"activeCount":67},[],{"intervention":381,"totalTrials":63,"cells":382},"rosuvastatin",{"EARLY_PHASE1":383,"PHASE1":385,"PHASE2":387,"PHASE3":389,"PHASE4":401,"NA":403},{"trials":384,"activeCount":67},[],{"trials":386,"activeCount":67},[],{"trials":388,"activeCount":67},[],{"trials":390,"activeCount":67},[391],{"nctId":392,"briefTitle":393,"status":394,"phases":395,"primaryCompletion":396,"start":397,"enrollment":17,"conditions":398,"interventions":400},"NCT00986999","Effect of Rosuvastatin on Endothelial Function","TERMINATED",[57,58],"2015-01","2009-09",[29,399],"Cardiovascular Disease",[381],{"trials":402,"activeCount":67},[],{"trials":404,"activeCount":67},[],{"intervention":406,"totalTrials":63,"cells":407},"metformin extended release",{"EARLY_PHASE1":408,"PHASE1":410,"PHASE2":412,"PHASE3":423,"PHASE4":425,"NA":427},{"trials":409,"activeCount":67},[],{"trials":411,"activeCount":67},[],{"trials":413,"activeCount":67},[414],{"nctId":415,"briefTitle":416,"status":290,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":101,"conditions":420,"interventions":422},"NCT02383563","Metformin for HIV Inflammation",[57],"2016-02","2015-02",[32,421],"Coronary Artery Disease",[406],{"trials":424,"activeCount":67},[],{"trials":426,"activeCount":67},[],{"trials":428,"activeCount":67},[],{"intervention":430,"totalTrials":63,"cells":431},"Noni extract",{"EARLY_PHASE1":432,"PHASE1":434,"PHASE2":436,"PHASE3":447,"PHASE4":449,"NA":451},{"trials":433,"activeCount":67},[],{"trials":435,"activeCount":67},[],{"trials":437,"activeCount":67},[438],{"nctId":439,"briefTitle":440,"status":394,"phases":441,"primaryCompletion":442,"completion":442,"start":443,"enrollment":10,"conditions":444,"interventions":446},"NCT02648919","Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer",[57],"2018-12","2015-12",[445],"Prostate Cancer",[430],{"trials":448,"activeCount":67},[],{"trials":450,"activeCount":67},[],{"trials":452,"activeCount":67},[],{"intervention":454,"totalTrials":63,"cells":455},"Telmisartan Oral Product",{"EARLY_PHASE1":456,"PHASE1":458,"PHASE2":460,"PHASE3":472,"PHASE4":474,"NA":476},{"trials":457,"activeCount":67},[],{"trials":459,"activeCount":67},[],{"trials":461,"activeCount":67},[462],{"nctId":463,"briefTitle":464,"status":394,"phases":465,"primaryCompletion":466,"completion":466,"start":467,"enrollment":468,"conditions":469,"interventions":471},"NCT04715763","INvestigating TELmisartin Study",[57],"2022-04-26","2021-09-01",24,[470],"Covid19",[454],{"trials":473,"activeCount":67},[],{"trials":475,"activeCount":67},[],{"trials":477,"activeCount":67},[],{"intervention":479,"totalTrials":63,"cells":480},"Denosumab",{"EARLY_PHASE1":481,"PHASE1":483,"PHASE2":485,"PHASE3":498,"PHASE4":500,"NA":502},{"trials":482,"activeCount":67},[],{"trials":484,"activeCount":67},[],{"trials":486,"activeCount":67},[487],{"nctId":488,"briefTitle":489,"status":394,"phases":490,"primaryCompletion":491,"completion":491,"start":492,"enrollment":63,"conditions":493,"interventions":494},"NCT02758132","Denosumab Plus Enzalutamide, Abiraterone and Prednisone Compared to Denosumab Plus Enzalutamide Alone for Men With Castrate Resistant Prostate Cancer (CRPC) With Bone Metastases",[57],"2016-09-06","2016-03-01",[445],[479,495,496,497],"Enzalutamide","Abiraterone","Prednisone",{"trials":499,"activeCount":67},[],{"trials":501,"activeCount":67},[],{"trials":503,"activeCount":67},[],{"intervention":495,"totalTrials":63,"cells":505},{"EARLY_PHASE1":506,"PHASE1":508,"PHASE2":510,"PHASE3":516,"PHASE4":518,"NA":520},{"trials":507,"activeCount":67},[],{"trials":509,"activeCount":67},[],{"trials":511,"activeCount":67},[512],{"nctId":488,"briefTitle":489,"status":394,"phases":513,"primaryCompletion":491,"completion":491,"start":492,"enrollment":63,"conditions":514,"interventions":515},[57],[445],[479,495,496,497],{"trials":517,"activeCount":67},[],{"trials":519,"activeCount":67},[],{"trials":521,"activeCount":67},[],{"intervention":496,"totalTrials":63,"cells":523},{"EARLY_PHASE1":524,"PHASE1":526,"PHASE2":528,"PHASE3":534,"PHASE4":536,"NA":538},{"trials":525,"activeCount":67},[],{"trials":527,"activeCount":67},[],{"trials":529,"activeCount":67},[530],{"nctId":488,"briefTitle":489,"status":394,"phases":531,"primaryCompletion":491,"completion":491,"start":492,"enrollment":63,"conditions":532,"interventions":533},[57],[445],[479,495,496,497],{"trials":535,"activeCount":67},[],{"trials":537,"activeCount":67},[],{"trials":539,"activeCount":67},[],{"intervention":497,"totalTrials":63,"cells":541},{"EARLY_PHASE1":542,"PHASE1":544,"PHASE2":546,"PHASE3":552,"PHASE4":554,"NA":556},{"trials":543,"activeCount":67},[],{"trials":545,"activeCount":67},[],{"trials":547,"activeCount":67},[548],{"nctId":488,"briefTitle":489,"status":394,"phases":549,"primaryCompletion":491,"completion":491,"start":492,"enrollment":63,"conditions":550,"interventions":551},[57],[445],[479,495,496,497],{"trials":553,"activeCount":67},[],{"trials":555,"activeCount":67},[],{"trials":557,"activeCount":67},[],{"intervention":559,"totalTrials":63,"cells":560},"gemcitabine and oxaliplatin",{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":579,"PHASE4":581,"NA":583},{"trials":562,"activeCount":67},[],{"trials":564,"activeCount":67},[],{"trials":566,"activeCount":67},[567],{"nctId":568,"briefTitle":569,"status":570,"phases":571,"primaryCompletion":572,"completion":573,"start":574,"enrollment":67,"conditions":575,"interventions":578},"NCT01524575","Gemcitabine and Oxaliplatin in the Management of Metastatic Pancreatic Cancers With Low Expression of ERCC1","WITHDRAWN",[57],"2013-07","2014-01","2012-01",[576,577],"Metastatic Pancreatic Cancer","ERCC1",[559],{"trials":580,"activeCount":67},[],{"trials":582,"activeCount":67},[],{"trials":584,"activeCount":67},[],{"intervention":586,"totalTrials":63,"cells":587},"cenicriviroc",{"EARLY_PHASE1":588,"PHASE1":590,"PHASE2":592,"PHASE3":604,"PHASE4":606,"NA":608},{"trials":589,"activeCount":67},[],{"trials":591,"activeCount":67},[],{"trials":593,"activeCount":67},[594],{"nctId":595,"briefTitle":596,"status":173,"phases":597,"primaryCompletion":598,"completion":598,"start":599,"enrollment":9,"conditions":600,"interventions":603},"NCT02128828","Effect of Cenicriviroc on HIV Neurocognitive Impairment",[57],"2016-06","2014-04",[347,601,602],"HIV-1-Associated Cognitive Motor Complex","Human Immunodeficiency Virus",[586],{"trials":605,"activeCount":67},[],{"trials":607,"activeCount":67},[],{"trials":609,"activeCount":67},[],{"intervention":611,"totalTrials":63,"cells":612},"Telmisartan 40mg",{"EARLY_PHASE1":613,"PHASE1":615,"PHASE2":617,"PHASE3":627,"PHASE4":629,"NA":631},{"trials":614,"activeCount":67},[],{"trials":616,"activeCount":67},[],{"trials":618,"activeCount":67},[619],{"nctId":620,"briefTitle":621,"status":394,"phases":622,"primaryCompletion":466,"completion":466,"start":623,"enrollment":468,"conditions":624,"interventions":626},"NCT04360551","Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients",[57],"2020-07-01",[625],"COVID-19",[611],{"trials":628,"activeCount":67},[],{"trials":630,"activeCount":67},[],{"trials":632,"activeCount":67},[],{"intervention":634,"totalTrials":63,"cells":635},"Tranexamic acid",{"EARLY_PHASE1":636,"PHASE1":638,"PHASE2":640,"PHASE3":654,"PHASE4":656,"NA":658},{"trials":637,"activeCount":67},[],{"trials":639,"activeCount":67},[],{"trials":641,"activeCount":67},[642],{"nctId":643,"briefTitle":644,"status":173,"phases":645,"primaryCompletion":646,"completion":646,"start":647,"enrollment":345,"conditions":648,"interventions":653},"NCT04651166","Effect of Prophylactic Tranexamic Acid on Bleeding Outcomes for Dilation and Evacuation",[57],"2023-07-27","2022-02-15",[649,650,651,652],"Abortion","Dilation and Evacuation","Hemorrhage","Blood Loss",[634],{"trials":655,"activeCount":67},[],{"trials":657,"activeCount":67},[],{"trials":659,"activeCount":67},[],{"intervention":661,"totalTrials":63,"cells":662},"Ferumoxytol",{"EARLY_PHASE1":663,"PHASE1":665,"PHASE2":676,"PHASE3":678,"PHASE4":680,"NA":682},{"trials":664,"activeCount":67},[],{"trials":666,"activeCount":67},[667],{"nctId":668,"briefTitle":669,"status":173,"phases":670,"primaryCompletion":671,"completion":671,"start":672,"enrollment":12,"conditions":673,"interventions":675},"NCT01665846","Ferumoxytol-enhanced Brain MRI in HIV-associated Neurocognitive Disorders",[56],"2012-06","2011-07",[674],"HIV Dementia",[661],{"trials":677,"activeCount":67},[],{"trials":679,"activeCount":67},[],{"trials":681,"activeCount":67},[],{"trials":683,"activeCount":67},[],{"intervention":685,"totalTrials":63,"cells":686},"Atezolizumab1200 mg IV",{"EARLY_PHASE1":687,"PHASE1":689,"PHASE2":702,"PHASE3":704,"PHASE4":706,"NA":708},{"trials":688,"activeCount":67},[],{"trials":690,"activeCount":67},[691],{"nctId":692,"briefTitle":693,"status":173,"phases":694,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":698,"interventions":700},"NCT03024216","Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer",[56],"2020-12-31","2017-02-06",37,[699],"Prostate Cancer Metastatic",[685,701],"Sipuleucel-T",{"trials":703,"activeCount":67},[],{"trials":705,"activeCount":67},[],{"trials":707,"activeCount":67},[],{"trials":709,"activeCount":67},[],{"intervention":701,"totalTrials":63,"cells":711},{"EARLY_PHASE1":712,"PHASE1":714,"PHASE2":720,"PHASE3":722,"PHASE4":724,"NA":726},{"trials":713,"activeCount":67},[],{"trials":715,"activeCount":67},[716],{"nctId":692,"briefTitle":693,"status":173,"phases":717,"primaryCompletion":695,"completion":695,"start":696,"enrollment":697,"conditions":718,"interventions":719},[56],[699],[685,701],{"trials":721,"activeCount":67},[],{"trials":723,"activeCount":67},[],{"trials":725,"activeCount":67},[],{"trials":727,"activeCount":67},[],{"intervention":729,"totalTrials":63,"cells":730},"Sorafenib",{"EARLY_PHASE1":731,"PHASE1":733,"PHASE2":743,"PHASE3":745,"PHASE4":747,"NA":749},{"trials":732,"activeCount":67},[],{"trials":734,"activeCount":67},[735],{"nctId":736,"briefTitle":737,"status":570,"phases":738,"primaryCompletion":293,"completion":293,"start":739,"enrollment":67,"conditions":740,"interventions":742},"NCT02288507","Sorafenib Concurrent With Yttrium-90 Transarterial Radioembolization in Patients With Advanced Hepatocellular Cancer",[56],"2014-11",[741],"Hepatocellular Cancer",[729],{"trials":744,"activeCount":67},[],{"trials":746,"activeCount":67},[],{"trials":748,"activeCount":67},[],{"trials":750,"activeCount":67},[],{"intervention":752,"totalTrials":63,"cells":753},"Paracervical Block with lidocaine",{"EARLY_PHASE1":754,"PHASE1":756,"PHASE2":758,"PHASE3":760,"PHASE4":762,"NA":764},{"trials":755,"activeCount":67},[],{"trials":757,"activeCount":67},[],{"trials":759,"activeCount":67},[],{"trials":761,"activeCount":67},[],{"trials":763,"activeCount":67},[],{"trials":765,"activeCount":67},[766],{"nctId":767,"briefTitle":768,"status":173,"phases":769,"primaryCompletion":443,"completion":443,"start":770,"enrollment":771,"conditions":772,"interventions":773},"NCT02454296","Paracervical Block for Pain Associated With Laminaria Insertion",[60],"2015-05",41,[251],[752,774],"Sham paracervical block",{"intervention":774,"totalTrials":63,"cells":776},{"EARLY_PHASE1":777,"PHASE1":779,"PHASE2":781,"PHASE3":783,"PHASE4":785,"NA":787},{"trials":778,"activeCount":67},[],{"trials":780,"activeCount":67},[],{"trials":782,"activeCount":67},[],{"trials":784,"activeCount":67},[],{"trials":786,"activeCount":67},[],{"trials":788,"activeCount":67},[789],{"nctId":767,"briefTitle":768,"status":173,"phases":790,"primaryCompletion":443,"completion":443,"start":770,"enrollment":771,"conditions":791,"interventions":792},[60],[251],[752,774],{"intervention":794,"totalTrials":63,"cells":795},"Doxycycline",{"EARLY_PHASE1":796,"PHASE1":798,"PHASE2":800,"PHASE3":802,"PHASE4":804,"NA":806},{"trials":797,"activeCount":67},[],{"trials":799,"activeCount":67},[],{"trials":801,"activeCount":67},[],{"trials":803,"activeCount":67},[],{"trials":805,"activeCount":67},[],{"trials":807,"activeCount":67},[808],{"nctId":809,"briefTitle":810,"status":173,"phases":811,"primaryCompletion":812,"completion":812,"start":813,"enrollment":9,"conditions":814,"interventions":816},"NCT01469585","Oral Contraceptives and Subantimicrobial Doxycycline: Effect on Endometrial Matrix Metalloproteinases",[60],"2012-05","2011-11",[815],"Breakthrough Bleeding",[794],{"intervention":818,"totalTrials":63,"cells":819},"Fentanyl",{"EARLY_PHASE1":820,"PHASE1":822,"PHASE2":824,"PHASE3":826,"PHASE4":828,"NA":830},{"trials":821,"activeCount":67},[],{"trials":823,"activeCount":67},[],{"trials":825,"activeCount":67},[],{"trials":827,"activeCount":67},[],{"trials":829,"activeCount":67},[],{"trials":831,"activeCount":67},[832],{"nctId":833,"briefTitle":834,"status":173,"phases":835,"primaryCompletion":836,"completion":836,"start":837,"enrollment":838,"conditions":839,"interventions":841},"NCT03057041","Intranasal Fentanyl for Pain Control During First-Trimester Uterine Aspiration",[60],"2018-05-30","2017-03-23",107,[840],"Pain Uterus",[818],{"intervention":843,"totalTrials":63,"cells":844},"intravenous oxytocin",{"EARLY_PHASE1":845,"PHASE1":847,"PHASE2":849,"PHASE3":851,"PHASE4":853,"NA":855},{"trials":846,"activeCount":67},[],{"trials":848,"activeCount":67},[],{"trials":850,"activeCount":67},[],{"trials":852,"activeCount":67},[],{"trials":854,"activeCount":67},[],{"trials":856,"activeCount":67},[857],{"nctId":858,"briefTitle":859,"status":173,"phases":860,"primaryCompletion":861,"completion":861,"start":862,"enrollment":863,"conditions":864,"interventions":865},"NCT02083809","Effects of Oxytocin on Bleeding Outcomes During Dilation and Evacuation",[60],"2018-02","2014-10",166,[649,650,651,652],[843,866],"Intravenous Fluids and Electrolytes",{"intervention":866,"totalTrials":63,"cells":868},{"EARLY_PHASE1":869,"PHASE1":871,"PHASE2":873,"PHASE3":875,"PHASE4":877,"NA":879},{"trials":870,"activeCount":67},[],{"trials":872,"activeCount":67},[],{"trials":874,"activeCount":67},[],{"trials":876,"activeCount":67},[],{"trials":878,"activeCount":67},[],{"trials":880,"activeCount":67},[881],{"nctId":858,"briefTitle":859,"status":173,"phases":882,"primaryCompletion":861,"completion":861,"start":862,"enrollment":863,"conditions":883,"interventions":884},[60],[649,650,651,652],[843,866],{"intervention":886,"totalTrials":63,"cells":887},"extended release niacin",{"EARLY_PHASE1":888,"PHASE1":890,"PHASE2":892,"PHASE3":894,"PHASE4":896,"NA":898},{"trials":889,"activeCount":67},[],{"trials":891,"activeCount":67},[],{"trials":893,"activeCount":67},[],{"trials":895,"activeCount":67},[],{"trials":897,"activeCount":67},[],{"trials":899,"activeCount":67},[900],{"nctId":901,"briefTitle":902,"status":173,"phases":903,"primaryCompletion":904,"completion":904,"start":905,"enrollment":9,"conditions":906,"interventions":909},"NCT00986986","Study of Niacin on Endothelial Function in HIV-infected Subjects With Low High Density Lipoprotein Cholesterol Levels",[60],"2010-04","2007-11",[29,907,908],"Dyslipidemia","Endothelial Dysfunction",[886]]